Tage Honoré
Vermögen: 572 030 $ am 30.06.2026
Vermögen: 572 030 $ am 30.06.2026
Dr. Tage Honoré is an Independent Director at Vanda Pharmaceuticals, Inc., a Head-Pharmaceutical Development at Avicenna Biosciences, Inc. and a President at Aestus Partners LLC.
He is on the Board of Directors at Vanda Pharmaceuticals, Inc. Dr. Honoré was previously employed as a Chairman by Dep-Xplora ApS.
He received his graduate degree from the University of Copenhagen and a doctorate degree from the University of Copenhagen.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.06.2026 | 93.469 ( 0,16 % ) | 572 030 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 15.03.2023 |
Avicenna Biosciences, Inc.
Avicenna Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that intends to redesign and optimize drug candidates | Corporate Officer/Principal | 01.01.2020 |
| Unternehmen | Position | Ende |
|---|---|---|
Dep-Xplora ApS
Dep-Xplora ApS BiotechnologyHealth Technology Develops non-steroidal anti-inflammatory drugs for arthritis pain | Vorsitzender | 01.03.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company, which focuses on the development and commercialization of therapies | Health Technology |
University of Copenhagen
University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dep-Xplora ApS
Dep-Xplora ApS BiotechnologyHealth Technology Develops non-steroidal anti-inflammatory drugs for arthritis pain | Health Technology |
Avicenna Biosciences, Inc.
Avicenna Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that intends to redesign and optimize drug candidates | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen